Graves' Disease Development During Sizofiran Treatment.

スポンサーリンク

概要

• 論文の詳細を見る

• It has been reported that various types of immunoactivators can induce Graves' disease. We describe here a case of Graves' disease during treatment with sizofiran, an immunoactivator. A 42-year-old woman who had previously been in an euthyroid state with Hashimoto's thyroiditis, experienced thyrotoxicosis during continuous administration of sizofiran as immunotherapy for endometrial carcinoma. Since the TSH receptor-antibody was positive, and a thyroid scintigram showed diffuse goiter and high uptake, she was diagnosed as having Graves' disease. It is suggested that the administration of sizofiran may be one of the triggers of Graves' disease.(Internal Medicine 41: 977-978, 2002)

著者

• MORITA Shigeki

  Internal Medicine, Japanese Red Cross-Nagasaki Atomic Bomb Hospital

• Morita Shigeki

  Internal Medicine Japanese Red Cross-nagasaki Atomic Bomb Hospital

• Ueda Yasuo

  Internal Medicine Japanese Red Cross-nagasaki Atomic Bomb Hospital

関連論文

• Transient Appearance of Lactate Dehydrogenase (LDH)-linked Immunoglobulin and Thyroid Dysfunction at the Postpartum Period
• Anti-Thyroid Drug-Induced ANCA-Associated Vasculitis: A Case Report and Review of the Literature
• Graves' Disease Associated with Goserelin Acetate
• Graves' Disease Development During Sizofiran Treatment
• Graves' Disease Development During Sizofiran Treatment.

スポンサーリンク